0.8743
1.66%
0.0143
アフターアワーズ:
.87
-0.0043
-0.49%
Kronos Bio Inc (KRON) 最新ニュース
Petri Dish: Kronos Bio seeks merger; Former Biogen R&D head joins investment firm - The Business Journals
Kronos Bio Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Kronos Bio Provides Update on Review of Strategic Alternatives - Marketscreener.com
Kronos Bio shares downgraded to hold by TD Cowen - Investing.com India
Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024 - The Manila Times
Kronos Bio Highlights Preclinical Data that Show p300 KAT - GlobeNewswire
Kronos Bio's KB-7898 Shows 50% Reduction in Inflammation Markers in Preclinical Study | KRON Stock News - StockTitan
Kronos Bio stock takes a hit with piper sandler slashing price target - Investing.com
Kronos mulls ‘strategic alternatives’ after axing cancer drug development - Pharmaceutical Technology
Kronos Bio (NASDAQ:KRON) Rating Lowered to "Hold" at TD Cowen - MarketBeat
Kronos Bio downgraded by Piper Sandler, TD Cowen (NASDAQ:KRON) - Seeking Alpha
TD Cowen Downgrades Kronos Bio (KRON) - MSN
Kronos Bio earnings beat by $0.05, revenue topped estimates - Investing.com UK
Kronos Bio, Inc. (KRON) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives - The Manila Times
Kronos Bio Reports Third Quarter 2024 Financial Results and - GlobeNewswire
Kronos Bio Halts Cancer Drug Trial, Explores Strategic Alternatives Amid Safety Concerns | KRON Stock News - StockTitan
Kronos Bio's Market Cap Drops To US$50m Leaving Insiders With Losses - Simply Wall St
Kronos Bio faces Nasdaq delisting over share price - Investing.com India
Kronos Bio faces Nasdaq delisting over share price By Investing.com - Investing.com UK
Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple Myeloma - GlobeNewswire
Kronos Bio to Present Breakthrough Multiple Myeloma Treatment Data at ASH 2024 | KRON Stock News - StockTitan
Non-Hodgkin’s Lymphoma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
Kronos Bio, Inc. (NASDAQ:KRON) Sees Large Decline in Short Interest - Defense World
Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace
Non-Hodgkin Lymphoma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
Nio Inc ADR (NIO-N) QuotePress Release - The Globe and Mail
Phillips-Van Heusen Corp (PVH-N) QuotePress Release - The Globe and Mail
After Plunging -23.49% in 4 Weeks, Here's Why the Trend Might Reverse for Kronos Bio (KRON) - MSN
Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors - The Manila Times
Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium - GlobeNewswire
Taylor Morrison Home Corp (TMHC-N) QuotePress Release - The Globe and Mail
Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors - The Manila Times
Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium - GlobeNewswire
Kronos Bio's (KRON) "Overweight" Rating Reaffirmed at Piper Sandler - MarketBeat
Kronos Bio nominates KAT inhibitor as development candidate for Sjögren’s disease - BioWorld Online
Piper Sandler maintains Overweight rating on Kronos Bio shares - Investing.com
Kronos Bio nominates KB-7898 for autoimmune disease treatment - Investing.com
Kronos Bio nominates KB-7898 for autoimmune disease treatment By Investing.com - Investing.com South Africa
Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren's Disease - The Manila Times
Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren’s Disease - GlobeNewswire
Plexium Announces Appointment of Jorge F. DiMartino, M.D., Ph.D. as Chief Medical Officer - PR Newswire
Kronos Bio, Inc. (NASDAQ:KRON) Position Increased by Forefront Analytics LLC - Defense World
Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory Therapy - StockTitan
Kronos Bio to Present Data at ACR Convergence 2024 to - GlobeNewswire
Keros Therapeutics (NASDAQ:KROS) Shares Gap Up to $55.80 - Defense World
Avoro Capital Advisors LLC Reduces Position in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Integral Health Asset Management LLC Acquires 45,000 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
How the (KROS) price action is used to our Advantage - Stock Traders Daily
How does Keros Therapeutics Inc (KROS) change from a tortoise to a hare? - SETE News
Kronos Bio highlights istisociclib data at Ovarian Cancer Research Symposium - TipRanks
大文字化:
|
ボリューム (24 時間):